Board of directors

Michal Votruba, MD


Physician, industry expert and investment professional, Dr. Votruba has been Director of the RSJ Gradus the first dedicated Life Sciences fund in Central Europe with a portfolio of companies in Europe and the United States. Dr. Votruba combined his theoretical and clinical experience in the field of Competitive Intelligence, serving as pharmaceutical industry analyst advising senior leaders of companies including Amgen, Novartis, Eli Lilly, Allergan, EMD, Serono, and Sanofi. Dr. Votruba serves as director for BioXcel Therapeutics (NASDAQ: BTAI), is a biopharmaceutical company developing transformative medicines in neuroscience utilizing artificial intelligence, and was a director of Mynd Analytics, Inc. (NASDAQ: MYND), a telebehavioral health services company. Since 2010, he has served as a member of the board of PrimeCell Therapeutics and as the Director of Global Business Development overseeing the expansion of the largest regenerative medicine company operating in Central Europe. 

In 2009, the Czech Academy of Sciences solicited Mr. Votruba’s expertise for the first successful privatization project of the Institute of Experimental Medicine in Prague. Dr. Votruba graduated as a Clinical Psychiatrist from the Medical Faculty of Charles University in Prague in 1989, and developed his professional career in Europe, Canada and the United States.